{
    "clinical_study": {
        "@rank": "146549", 
        "brief_summary": {
            "textblock": "OBJECTIVES:\n\n      I. Determine the response rate and 1-year event-free survival in patients with severe\n      autoimmune hematologic disease treated with high-dose cyclophosphamide."
        }, 
        "brief_title": "Phase II Study of High-Dose Cyclophosphamide in Patients With Severe Autoimmune Hematologic Disease", 
        "condition": [
            "Anemia, Hemolytic, Autoimmune", 
            "Felty Syndrome", 
            "Purpura, Thrombocytopenic", 
            "Autoimmune Diseases"
        ], 
        "condition_browse": {
            "mesh_term": [
                "Anemia", 
                "Anemia, Hemolytic", 
                "Anemia, Hemolytic, Autoimmune", 
                "Autoimmune Diseases", 
                "Felty's Syndrome", 
                "Hematologic Diseases", 
                "Purpura", 
                "Hemolysis", 
                "Purpura, Thrombocytopenic"
            ]
        }, 
        "detailed_description": {
            "textblock": "PROTOCOL OUTLINE: Patients receive high-dose cyclophosphamide IV on days 1-4 and filgrastim\n      (G-CSF) starting on day 10 and continuing until blood counts recover.\n\n      Patients are followed at 1, 3, 6, and 12 months and then annually thereafter."
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "PROTOCOL ENTRY CRITERIA:\n\n        --Disease Characteristics--\n\n          -  Diagnosis of severe autoimmune hematologic disease Autoimmune hemolytic anemia OR\n             Immune thrombocytopenia\n\n          -  Failure of at least 2 standard treatment approaches (e.g., prednisone therapy,\n             splenectomy, intravenous immunoglobulin, or other immunosuppressants)\n\n          -  Inability to taper prednisone dose to less than 10 mg/day OR Autoimmune neutropenia\n             including the following: Felty's syndrome OR Disorders of large granular lymphocytes\n             with recurrent infections or absolute neutrophil count less than 200/mm3\n\n        --Prior/Concurrent Therapy--\n\n          -  See Disease Characteristics\n\n        --Patient Characteristics--\n\n          -  Age: Not specified\n\n          -  Performance status: Not specified\n\n          -  Hematopoietic: See Disease Characteristics\n\n          -  Hepatic: Not specified\n\n          -  Renal: Creatinine no greater than 2.5 mg/dL\n\n          -  Cardiovascular: Ejection fraction at least 40%\n\n          -  Pulmonary: FVC, FEV1, or DLCO at least 50% predicted\n\n        Other:\n\n          -  Not pregnant or nursing\n\n          -  Negative pregnancy test\n\n          -  Fertile patients must use effective contraception\n\n          -  Not preterminal or moribund"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "N/A"
        }, 
        "enrollment": "32", 
        "firstreceived_date": "February 2, 2001", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT00010387", 
            "org_study_id": "199/15672", 
            "secondary_id": [
                "JHOC-J9881", 
                "JHOC-99012906"
            ]
        }, 
        "intervention": [
            {
                "intervention_name": "cyclophosphamide", 
                "intervention_type": "Drug"
            }, 
            {
                "intervention_name": "filgrastim", 
                "intervention_type": "Drug"
            }
        ], 
        "intervention_browse": {
            "mesh_term": [
                "Cyclophosphamide", 
                "Lenograstim"
            ]
        }, 
        "keyword": [
            "Felty syndrome", 
            "autoimmune hemolytic anemia", 
            "autoimmune neutropenia", 
            "hematologic disorders", 
            "immune thrombocytopenic purpura", 
            "rare disease"
        ], 
        "lastchanged_date": "September 8, 2008", 
        "location": {
            "facility": {
                "address": {
                    "city": "Baltimore", 
                    "country": "United States", 
                    "state": "Maryland", 
                    "zip": "21231"
                }, 
                "name": "Johns Hopkins Oncology Center"
            }
        }, 
        "location_countries": {
            "country": "United States"
        }, 
        "overall_official": {
            "affiliation": "Johns Hopkins University", 
            "last_name": "Robert A. Brodsky", 
            "role": "Study Chair"
        }, 
        "overall_status": "Completed", 
        "oversight_info": {
            "authority": "Unspecified"
        }, 
        "phase": "Phase 2", 
        "primary_completion_date": {
            "#text": "August 2007", 
            "@type": "Actual"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT00010387"
        }, 
        "source": "Office of Rare Diseases (ORD)", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Johns Hopkins University", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "March 1999", 
        "study_design": "Intervention Model: Single Group Assignment, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "September 2008"
    }, 
    "geocoordinates": {
        "Johns Hopkins Oncology Center": "39.29 -76.612"
    }
}